MAOB and Parkinson disease: A recent MDS systematic review concluded that, in PD-MCI, the monoamine oxidase B (MAO-B) inhibitors rasagiline and rivastigmine presented an acceptable risk of adverse events, without specialized monitoring, but there is still insufficient evidence on their efficacy [44].